Multivalent Porous Silicon Nanoparticles Enhance the Immune Activation Potency of Agonistic CD40 Antibody

被引:71
|
作者
Gu, Luo [1 ]
Ruff, Laura E. [2 ]
Qin, Zhengtao [1 ]
Corr, Maripat [3 ]
Hedrick, Stephen M. [4 ]
Sailor, Michael J. [1 ]
机构
[1] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
CROSS-PRESENTATION; DRUG-DELIVERY; QUANTUM DOTS; CELLS; MICROPARTICLES; IMMUNOTHERAPY; RESPONSES; INTERNALIZATION; DISSOLUTION; INDUCTION;
D O I
10.1002/adma.201200776
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
One of the fundamental paradigms in the use of nanoparticles to treat disease is to evade or suppress the immune system in order to minimize systemic side effects and deliver sufficient nanoparticle quantities to the intended tissues. However, the immune system is the body's most important and effective defense against diseases. It protects the host by identifying and eliminating foreign pathogens as well as self-malignancies. Here we report a nanoparticle engineered to work with the immune system, enhancing the intended activation of antigen presenting cells (APCs). We show that luminescent porous silicon nanoparticles (LPSiNPs), each containing multiple copies of an agonistic antibody (FGK45) to the APC receptor CD40, greatly enhance activation of B cells. The cellular response to the nanoparticle-based stimulators is equivalent to a 30-40 fold larger concentration of free FGK45. The intrinsic near-infrared photoluminescence of LPSiNPs is used to monitor degradation and track the nanoparticles inside APCs.
引用
收藏
页码:3981 / 3987
页数:7
相关论文
共 50 条
  • [21] A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
    Victor Moreno
    Ruth Perets
    Tamar Peretz-Yablonski
    Nele Fourneau
    Suzette Girgis
    Yue Guo
    Peter Hellemans
    Raluca Verona
    Natalia Pendás
    Qi Xia
    Ravit Geva
    Emiliano Calvo
    Investigational New Drugs, 2023, 41 : 93 - 104
  • [22] Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
    Fransen, Marieke F.
    Sluijter, Marjolein
    Morreau, Hans
    Arens, Ramon
    Melief, Cornelis J. M.
    CLINICAL CANCER RESEARCH, 2011, 17 (08) : 2270 - 2280
  • [23] A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
    Moreno, Victor
    Perets, Ruth
    Peretz-Yablonski, Tamar
    Fourneau, Nele
    Girgis, Suzette
    Guo, Yue
    Hellemans, Peter
    Verona, Raluca
    Pendas, Natalia
    Xia, Qi
    Geva, Ravit
    Calvo, Emiliano
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (01) : 93 - 104
  • [24] Immune activation during the implantation phase causes preeclampsia-like symptoms via the CD40–CD40 ligand pathway in pregnant mice
    Keiichi Matsubara
    Yuko Matsubara
    Miki Mori
    Yuka Uchikura
    Katsuyuki Hamada
    Toru Fujioka
    Hisashi Hashimoto
    Takashi Matsumoto
    Hypertension Research, 2016, 39 : 407 - 414
  • [25] Bispecific CD40/FAP DARPin® molecule for tumor-restricted immune activation
    Rigamonti, N.
    Schlegel, A.
    Barsin, S.
    Schwestermann, J.
    Krieg, J.
    Mangold, S.
    Paladino, M.
    Bruckmaier, S.
    Calabro, V.
    Levitsky, V.
    Plyte, S.
    Stumpp, M.
    Metz, C.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E78 - E78
  • [26] Chronic Immune Activation in HIV-1 Infection Contributes to Reduced Interferon Alpha Production via Enhanced CD40:CD40 Ligand Interaction
    Donhauser, Norbert
    Pritschet, Kathrin
    Helm, Martin
    Harrer, Thomas
    Schuster, Philipp
    Ries, Moritz
    Bischof, Georg
    Vollmer, Joerg
    Smola, Sigrun
    Schmidt, Barbara
    PLOS ONE, 2012, 7 (03):
  • [27] Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma
    Bajor, David L.
    Xu, Xiaowei
    Torigian, Drew A.
    Mick, Rosemarie
    Garcia, Laura R.
    Richman, Lee P.
    Desmarais, Cindy
    Nathanson, Katherine L.
    Schuchter, Lynn M.
    Kalos, Michael
    Vonderheide, Robert H.
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (11) : 1051 - 1058
  • [28] THE ROLE OF CD72 IN THE REGULATION OF B CELL ACTIVATION THROUGH CD40 IN PRIMARY IMMUNE THROMBOCYTOPENIA
    Lyu, M.
    Hao, Y.
    Li, Y.
    Liu, W.
    Lyu, C.
    Wang, S.
    Guan, Y.
    Li, H.
    Yang, R.
    HAEMATOLOGICA, 2016, 101 : 307 - 307
  • [29] First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
    Irenaeus, Sandra M. M.
    Nielsen, Dorte
    Ellmark, Peter
    Yachnin, Jeffrey
    Deronic, Adnan
    Nilsson, Anneli
    Norlen, Per
    Veitonmaki, Niina
    Wennersten, Camilla S.
    Ullenhag, Gustav J.
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (05) : 1189 - 1199
  • [30] Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia
    Delgado, Raquel
    Kielbassa, Karoline
    ter Burg, Johanna
    Klein, Christian
    Trumpfheller, Christine
    de Heer, Koen
    Kater, Arnon P.
    Eldering, Eric
    CANCERS, 2021, 13 (12)